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Social inhibition modulates the effect of negative
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coronary intervention in the drug-eluting stent era{
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Aims Negative emotions have an adverse effect on cardiac prognosis. We investigated whether social
inhibition (inhibited self-expression in social interaction) modulates the effect of negative emotions
on clinical outcome following percutaneous coronary intervention (PCI).
Methods and results Eight hundred and seventy-five consecutive patients from the RESEARCH registry
(Erasmus Medical Centre, Rotterdam) completed depression, anxiety, negativity (negative emotions in
general), and social inhibition scales 6 months following PCI. The endpoint was major adverse cardiac
event (MACE—death, myocardial infarction, coronary artery bypass graft (CABG), or PCI) at 9 months
following assessment. There were 100 MACE; patients who were high in both negativity and inhibition
were at increased risk of MACE (38/254 ¼ 15%) when compared with high negativity/low inhibition
patients (13/136 ¼ 10%; P ¼ 0.018). Depression (P ¼ 0.23) or anxiety (P ¼ 0.63) did not explain away
this moderating effect of inhibition. High negativity/high inhibition (HR ¼ 1.92, 95%CI 1.22–3.01,
P ¼ 0.005) and previous CABG (HR ¼ 1.90, 95%CI 1.04–3.47, P ¼ 0.038) were independent predictors
of MACE. Patients with high negativity but low inhibition were not at increased risk (P ¼ 0.76). High
negativity/high inhibition also independently predicted death/MI (n ¼ 20) as a more specific endpoint
(HR ¼ 5.85, P ¼ 0.001).
Conclusion The interaction effect of social inhibition and negative emotions, rather than negative
emotions per se, predicted poor clinical outcome following PCI. Social inhibition should not be
overlooked as a modulating factor.
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Introduction
The advent of drug-eluting stents has led to a reduction in
repeat revascularization following percutaneous coronary
intervention (PCI), but has not been shown to reduce the
risk of death or myocardial infarction (MI).1–3 Negative
emotions may have an adverse effect on prognosis and treat-
ment outcome in cardiac patients.4–6 However, the effect of
emotions has yet to be examined in the drug-eluting stent
era; in general, little is also known about psychological
factors that may modulate the impact of these emotions
on cardiac prognosis.
Social isolation may potentiate the adverse effect of
negative emotions. Post-MI patients with high levels of both
stress and social isolation had four times the risk of death
when compared with patients with low levels of stress/
isolation7; a recent study of mortality in the elderly also
found that isolation aggravates the adverse effect of
negative emotions.8 Social isolation is a function of individ-
ual differences in behavioural inhibition9; the trait ‘social
inhibition’ refers to the tendency to inhibit the expression
of emotion and behaviour in social interaction.10 Inhibited
individuals expect negative reactions from others and tend
to be socially isolated.
Preliminary evidence suggests that social inhibition may
also affect the clinical course of patients who have been
treated with PCI. Potential pathways through which social
inhibition may influence prognosis include enhanced
cardiovascular reactivity to stress,11–13 reduced heart
rate variability,14 and increased inflammation.15 Social inhi-
bition may also impede communication between patient
and physician and result in the under-treatment of psycho-
logical stress, which could be potentially damaging to
health.16 Finally, the socially inhibited are less likely to
adhere to treatment17 or to engage in health-promoting
behaviour.18
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We therefore examined the role of social inhibition in
the 15-month prognosis of PCI patients, who were treated
with bare or sirolimus-coated stenting in the Rapamycin-
Eluting Stent Evaluated at Rotterdam Cardiology Hospital
(RESEARCH) registry.3 Initial findings from this registry indi-
cated that Type D patients were at increased risk for death
or MI.19 Type D personality refers to patients who are high
in negative affectivity (tendency to experience negative
emotions) and social inhibition.20 These two components
of Type D were not analysed separately in this report, and
the endpoint did not include revascularization procedures19;
hence, it is possible that the increase in risk was attribu-
table to the main effect of either negative affectivity or
social inhibition and not that inhibition modulates the
effect of negative affectivity. In the present study, we there-
fore examined whether it is the specific interaction effect
of social inhibition and negative affectivity that renders
Type D patients at increased risk for death, MI, or repeat
revascularization following PCI treatment with stenting.
Methods
Patient population
Details of the RESEARCH registry have been published elsewhere.3,19
In brief, the purpose of the registrywas to investigate the efficacy and
safety of the sirolimus-eluting stent (SES) (Cypher; Johnson &
Johnson-Cordis unit, Cordis Europa NV, Roden, The Netherlands) in
PCI. Between October 2001 and October 2002, 1237 consecutive
patients with ischaemic heart disease were included. Prior to
April 2002, all patients received bare metal stents; since April
2002, all patients received the SES stent. All interventions were
performed according to current standard guidelines. One-month
clopidogrel treatment (75 mg/day) was recommended for patients
treated with bare stents; SES-patients received clopidogrel for
3 months. If patients had had multiple SES implantations, total
stented length .36 mm, chronic total occlusion, bifurcations, or
treatment of in-stent restenosis, clopidogrel was maintained for at
least 6 months. All patients were advised to maintain lifelong aspirin.
At 6-month post-PCI, all living patients were contacted by letter
and asked to fill in questionnaires19; 875 patients (71%) returned
the questionnaires (Table 1). Non-responders were younger (59 vs.
62 years, P, 0.001), more likely to have had a previous MI (18 vs.
14%, P ¼ 0.03), to suffer from diabetes (20 vs. 15%, P ¼ 0.02), and
to be treated with ACE-inhibitors (31 vs. 26%, P ¼ 0.04), but less
likely to suffer from renal impairment (23 vs. 31%, P, 0.01) and
to be treated with beta-blockers (26 vs. 51%, P, 0.001) or aspirin
(33 vs. 65%, P, 0.001) than responders. The study was approved
by the local hospital Ethics Committee and was carried out in
accordance with the Helsinki Declaration. Every patient provided
written informed consent.
Social inhibition
The patient’s level of inhibition was assessed with the ‘social
inhibition’ subscale of the Type D Personality Scale (DS14)21; this
Table 1 Baseline characteristics at 6-month post-PCI (n ¼ 875)
Total group
(n/875)%
Personality subgroups Pa
Negativity2
(n/485)%
Negativityþ
Inhibition2
(n/136)%
Inhibitionþ
(n/254)%
Demographics
Age (years), mean (+SD) 62.2 (10.9) 62.9 (10.7) 61.6 (10.4) 61.1 (11.6) 0.095
Male gender 72% (629) 75% (364) 65% (88) 70% (177) 0.039
Stent type
Sirolimus-eluting stent 41% (358) 40% (192) 44% (60) 42% (106) 0.61
Clinical risk factors
Multi-vessel disease 52% (458) 52% (253) 52% (70) 53% (135) 0.95
Previous MI 37% (327) 36% (175) 40% (54) 39% (98) 0.66
Previous CABG 12% (101) 12% (57) 12% (16) 11% (28) 0.95
Previous PCI 25% (219) 23% (109) 32% (44) 26% (66) 0.058
Hypercholesterolaemiab 81% (709) 79% (381) 84% (114) 84% (214) 0.11
Hypertension 39% (339) 38% (183) 38% (52) 41% (104) 0.69
Smoking 31% (273) 29% (138) 29% (40) 37% (95) 0.040
Renal impairmentc 30% (265) 30% (145) 28% (37) 33% (83) 0.56
Diabetes mellitus 15% (127) 11% (54) 22% (30) 17% (43) 0.003
Medication
Beta-blockers 98% (856) 98% (474) 96% (131) 99% (251) 0.43
Aspirin 96% (840) 96% (466) 97% (132) 95% (242) 0.69
Clopidogrel 95% (830) 95% (461) 93% (127) 95% (242) 0.69
Statins 67% (589) 66% (321) 70% (95) 68% (173) 0.69
Calcium antagonists 47% (409) 47% (227) 45% (61) 48% (121) 0.87
ACE-inhibitors 26% (225) 26% (126) 26% (35) 25% (64) 0.97
Nitrates 10% (83) 9% (42) 12% (16) 10% (25) 0.54
Negativity2: patients who score low on negative affectivity, irrespective of level of Inhibition; negativityþ/inhibition2: patients who score high on
negative affectivity but low on inhibition; negativityþ/inhibitionþ: patients who score high on negative affectivity and inhibition. Previous MI, myocardial
infarction prior to index event; previous PCI, percutaneous coronary intervention prior to index event; previous CABG, bypass surgery prior to index event.
aA post hoc Bonferroni correction was applied to all tests to adjust for multiple comparisons with P, 0.02 (0.05/3) indicating statistical significance.
bTotal cholesterol levels .240 mg/dL or on lipid lowering medication.
cIndicated by creatine clearance ,61 mL/min.
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subscale measures the tendency to inhibit the expression of
emotion/behaviour in order to avoid negative reactions from
others, such as disapproval. High scorers tend to feel inhibited,
tensed, and insecure when with others. Each of the seven inhibition
items (e.g. ‘I am a closed kind of person’, ‘I often feel inhibited in
social interactions’) is rated on a five-point Likert scale (0–4). The
subscale is valid, internally consistent (Cronbach’s a ¼ 0.86), and
stable over a 3-month period (test-retest r ¼ 0.82). According to a
previously established cut-off, patients scoring 10 are considered
high in inhibition.21
Negative emotions
Symptoms of depression22 and anxiety23 are markers of negative
emotional conditions and have been linked to poor prognosis in
post-MI patients. The ‘depression’ subscale of the Hospital Anxiety
and Depression Scale (HADS) was used to evaluate depressive symp-
toms.24 This subscale consists of seven items, which are answered
on a four-point Likert scale (0–3; total score range 0–21), has
good reliability and validity,25 and correlates well with the clinical
diagnosis of post-MI depression.26 A cut-off score of 8 yields an
optimal balance between sensitivity and specificity25 and was used
to determine elevated depression scores. The seven-item
‘anxiety’ subscale of the HADS was used to evaluate anxiety symp-
toms (total score range 0–21).24 A cut-off score of 8 was used
to determine elevated anxiety scores.25 The ‘negative affectivity’
subscale of the DS14 was used to assess individual differences in
patients’ tendencies to experience negative emotions in general,
that is, high scorers tend to report feelings of depression, anxiety,
or irritability across time and situations. This seven-item subscale
is valid, consistent (Cronbach’s a ¼ 0.88), and stable (test-retest
r ¼ 0.72).21 In this article, the term ‘negativity’ will be used to
refer to individual differences in negative affectivity. According
to a previously established cut-off, patients scoring 10 are
considered high in negativity.21
Biomedical factors
Information on stent type (SES vs. bare metal stent) and clinical
variables [multi-vessel disease, previous MI, previous coronary
artery bypass graft (CABG) surgery, previous PCI] were obtained
from the patients’ medical records. Standard cardiac risk factors
included age, gender, hypercholesterolaemia, hypertension,
smoking status, renal impairment, and diabetes mellitus. Medical
treatment was also recorded, including prescription of beta-
blockers, aspirin, clopidogrel, statins, calcium antagonists,
ACE-inhibitors, and nitrates.
Endpoint
The endpoint was the occurrence of a major adverse cardiac event
(MACE), defined as a composite of death, MI, CABG, or repeat PCI
at 9 months following psychological assessment. Data on these
endpoints were available for all patients. MI was diagnosed by a
rise in the creatine kinase level to more than twice the upper
normal limit with an increased creatine kinase-MB. Events occurring
between the index event and administration of questionnaires were
excluded as an endpoint. Non-fatal MI, CABG, or PCI that occurred
prior to psychological assessment were included in the analyses as
previous MI, previous CABG, or previous PCI.
Statistical analyses
Principal components analysis (varimax rotation) of items from the
inhibition, depression, anxiety, and negativity scales was used to
examine the structural validity of the social inhibition construct,
that is, the ability of the inhibition items to reflect a psychological
construct that is distinctly different from self-reported negative
emotions.27 The scree-plot was used as a criterion for the number
of factors to extract; Cronbach’s a was used to examine the internal
consistency of the inhibition scale. On the basis of their personality
test scores, patients were classified into one of three subgroups:
(i) low negativity, (ii) high negativity but low inhibition, or (iii)
high negativity and high inhibition. The x2 test (Fisher’s exact test
when appropriate) was used to compare these three subgroups on
baseline characteristics, and a post hoc Bonferroni correction was
used to adjust for multiple comparisons with P, 0.02 (0.05/3),
indicating statistical significance. Cox-regression analyses were per-
formed to investigate the relative impact of depressive, anxiety,
and negativity symptoms, and their interaction with social inhibition
on MACE at 9-months follow-up. Non-significant interaction terms
between variables and time to MACE (all P-values .0.10) showed
that the hazard ratios were constant across time, indicating that
the proportional hazards assumption was met. In multi-variable
analyses, age, gender, stent type (SES vs. bare stent), multi-vessel
disease, previous MI, previous CABG, previous PCI, hypertension,
smoking, hypercholesterolaemia, renal impairment, diabetes, and
psychological variables were entered at the same time. We chose
to adjust for these covariates, as sex and age are included stan-
dardly in multi-variable models in biobehavioural research and
have been associated with substantial variation in cardiovascular
outcomes; stent type was included, as there is as yet no knowledge
of the impact of drug-eluting stents on psychological functioning;
multi-vessel disease and cardiac history were included to adjust
for disease severity, ruling out the possibility that any relationship
between psychological variables and MACE could be due to more
severe cardiac disease in emotionally distressed patients; standard
risk factors, renal impairment, and diabetes were included to
control for somatic comorbidity. All statistical tests were two-
tailed; P-value ,0.05 was used to indicate statistical significance.
Hazard ratios with 95% confidence intervals are reported. Analyses
were performed using SPPS version 12.0.
Results
Social inhibition vs. negative emotions
Factor analysis was used to examine the structural validity
of the social inhibition construct. Consistent with the theor-
etical model of the present study, the scree-plot yielded two
dominant psychological factors that were assessed by ques-
tionnaires in the RESEARCH registry (Figure 1). Succeeding
factors were much smaller (eigenvalue ,1.0) and explained
a minor proportion of variance in distress. All inhibition
items loaded on one and the same factor, whereas all
items referring to negative emotions (depression, anxiety,
negativity) loaded on the other factor.
Figure 1 Scree plot showing the factors representing negative emotions and
social inhibition. This scree-plot indicated a marked ‘elbow’ that inflected
after the second factor; succeeding factors only explained a minor proportion
of variance in psychological functioning.
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Factor analysis of the seven social inhibition items and
the six items of negative emotions with the highest factor
loadings (two items for depression, anxiety, and negativity,
respectively) showed that the inhibition items loaded
much higher on their corresponding factor than on the
negative emotions factor (Table 2, factor analysis). In
addition, Cronbach’s a ¼ 0.86 and item-to-total correlations
ranging from 0.49 to 0.71 indicated a high level of internal
consistency for the inhibition scale (Table 2, last column).
These analyses confirmed that social inhibition represents
a homogeneous construct that is distinctly different from
negative emotions.
Characteristics of negativity/inhibition
subgroups
Stratifying baseline characteristics by negativity and inhi-
bition subgroups showed that males and diabetic patients
were more prevalent in the low negativity group (Table 1,
subgroups). There was also a trend for previous PCI, with
the high negativity/low inhibition subgroup being more
likely to have undergone PCI prior to the index procedure.
Finally, patients who were high in both negativity and
inhibition were more likely to be current smokers.
Negativity, inhibition, and cardiac events
At follow-up, there were 100 MACE. None of the medical
treatment variables (beta-blockers, aspirin, clopidogrel,
statins, calcium antagonists, ACE-inhibitors, or nitrates)
were significantly associated with clinical outcome.
Previous CABG (HR ¼ 1.78, 95%CI 1.05–3.02, P ¼ 0.032)
was associated with increased risk of MACE in univariate
analyses. The interaction between inhibition and negativity
was also associated with an increased risk of MACE
(HR ¼ 1.66, 95%CI 1.11–2.51, P ¼ 0.015), whereas nega-
tivity by itself did not predict outcome. Hence, inhibition
significantly modulated the effect of negativity on clinical
outcome following PCI, adjusting for stent type (SES vs.
bare metal stent), age, and gender (Figure 2).
The rate of MACE for patients who were high in negativity
but low in inhibition (9.6%) did not differ from that for
patients who were low in negativity (10.1%) and was
smaller than that for patients who were high in both
negativity/inhibition (15.0%; HR ¼ 1.64, 95%CI 1.09–2.47,
P ¼ 0.018). HADS scores of depressive symptoms (P ¼ 0.23)
or anxiety symptoms (P ¼ 0.63) did not explain away this
association between high negativity/high inhibition and
adverse cardiac prognosis. Hence, the increase in risk of
MACE was attributable to the interaction effect of high
negativity and high inhibition, but not to the main effect
of negative emotions.
In order to ascertain that the increased risk of MACE in the
high negative affectivity/high social inhibition group is not
merely due to a high score on negative affectivity, we inves-
tigated the mean (SD) scores between the three personality
subgroups, using ANOVA with a post hoc (Student–Newman–
Keuls) test. The mean (SD) score for the low negativity
regardless of inhibition group was 4.15 (2.95); for the high
negativity/low inhibition, it was 14.90 (4.15); for the high
negativity/high inhibition group, the mean was 16.44
(4.62). Differences between all groups were statistically
significant at P , 0.05. It should be noted, however, that
the mean difference (1.54) between Groups 2 and 3 cannot
be considered clinically relevant also considering the SDs
for each group. These additional results suggest that the
increased risk of MACE in the high negativity/high inhibition
group cannot be attributed to a high NA score alone.
Table 2 Social inhibition: factor structure and internal consistency (n ¼ 875)
Scale (Item) Factor analysis Internal consistencya
Factor 1 Factor 2
Social inhibition
DS14-SI (8) Has difficulties starting a conversation 0.78 0.19 0.71
DS14-SI (14) Does not find things to talk about 0.77 0.15 0.67
DS14-SI (10) Is closed kind of person 0.73 0.15 0.63
DS14-SI (11) Tends to keep others at a distance 0.73 0.14 0.63
DS14-SI (6) Is inhibited in social interactions 0.71 0.30 0.65
DS14-SI (1) Makes contact easily when
meeting peopleb
20.76 20.10 0.66
DS14-SI (3) Often talks to strangersb 20.62 20.05 0.49
a ¼ 0.86
Negative emotions
HADS-D (4) Does not laugh at all (depression) 0.17 0.74
HADS-D (2) Does not enjoy things in life
(depression)
0.14 0.73
HADS-A (1) Feels tense (anxiety) 0.10 0.79
HADS-A (5) Has worrying thoughts (anxiety) 0.08 0.78
DS14-NA (13) Tends to be down in the dumps
(negativity)
0.24 0.80
DS14-NA (12) Tends to worry a lot (negativity) 0.19 0.79
Factor loadings are presented in bold.
aCorrected item-to-total correlations.
bReverse keyed.
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Independent predictors of cardiac events
To determine whether medical and psychological factors
were independent predictors of cardiac events, we
entered these factors in a multi-variable Cox-regression
model (Table 3). Potential psychological risk factors
included the combinations of high negativity/low inhibition
and high negativity/high inhibition as distinctly different
subgroups. The final Cox-regression model retained high
negativity/high inhibition (HR ¼ 1.92, P ¼ 0.005) and history
of CABG (HR ¼ 1.90, P ¼ 0.038) as independent predictors of
adverse cardiac events; there was also a trend for diabetes
(P ¼ 0.073). In contrast, PCI patients who were high in nega-
tivity but low in inhibition were not at increased risk for
adverse clinical events during follow-up (P ¼ 0.76).
These findings were replicated in secondary analyses,
using a composite of death and MI as a more specific
endpoint (n ¼ 20). Rate of death/MI was 7/485 ¼ 1.4% for
patients who were low in negativity. Of note, 13 out of
254 patients who were high in both negativity and inhibition
died or had an MI. In contrast, none of the 136 patients who
were high in negativity but low in inhibition had one of these
events (5.1 vs. 0% event rate, P ¼ 0.004). Cox-regression
analysis yielded history of CABG, male gender, and high
negativity/high inhibition (HR ¼ 5.85, P ¼ 0.001), but not
high negativity/low inhibition (P ¼ 0.98), as independent
predictors of death/MI.
Discussion
The present findings showed that social inhibition is a
distinctly different psychological construct than negative
emotions and that inhibition modulates the impact of
these emotions on prognosis. More specifically, it was the
interaction between inhibition and negativity that predicted
the composite endpoint of death, MI, and repeat
revascularization at 9-month follow-up, adjusting for
medical confounders. This inhibition/negativity interaction
effect was associated with a 92% increase in risk of cardiac
events. Finally, concurrent symptoms of depression or
anxiety did not explain away the modulating effect of
inhibition on negativity as a predictor of poor clinical
outcome. These results were also confirmed in secondary
analyses using ‘hard events’ (i.e. death/MI) as an endpoint,
indicating that the interaction effect of inhibition and
negativity on clinical outcome following PCI was not only
symptom-driven.
Patients who display this combination of high inhibition
and high negativity are referred to as patients with a Type
D personality.20 The present findings are consistent with
those from previous studies showing that Type D indepen-
dently predicts long-term cardiac events.6,20,28 However,
only one study to date specifically looked at the interaction
between inhibition and negativity and found that the high
mortality risk among Type D patients was not attributable
to the main effect of either inhibition or negativity, but
rather to their interaction effect.20 In the present study,
the presence of negativity also had no effect on prognosis,
that is, patients with high negativity but low inhibition
were not at increased risk. The findings of two recent
meta-analyses indicated that depression is a risk factor
for adverse prognosis.29,30 The present results indicate
that social inhibition may significantly modulate this
relationship.
The present findings have important implications for clini-
cal research and practice: (i) this study is the first to confirm
the initial observation20 that it is the modulating effect
of social inhibition on negative emotions, which renders
patients at increased risk for cardiac events and (ii) provides
Figure 2 MACE stratified by negativity and inhibition. The number of
patients is presented on top of each bar. Negativity2: patients who score
low on negative affectivity, irrespective of level of inhibition; negativityþ/
inhibition2: patients who score high on negative affectivity but low on inhi-
bition; negativityþ/inhibitionþ: patients who score high on negative affec-
tivity and inhibition. Adjusted for age, gender and stent type.
Table 3 Multi-variable predictors of cardiac events post-PCI
(n ¼ 875)
Hazard ratio
(95%CI)
P
Demographics
Age 60 1.03 (0.65–1.61) 0.92
Female gender 1.33 (0.81–2.17) 0.26
Stent type
Sirolimus-eluting stent 0.79 (0.51–1.22) 0.28
Clinical factors
Multi-vessel disease 0.89 (0.57–1.37) 0.58
Previous MI 0.71 (0.46–1.12) 0.14
Previous CABG 1.90 (1.04–3.47) 0.038
Previous PCI 1.30 (0.81–2.09) 0.28
Hypercholesterolaemia 0.69 (0.42–1.14) 0.15
Hypertension 0.87 (0.56–1.34) 0.52
Smoking 0.69 (0.42–1.12) 0.13
Renal impairment 0.85 (0.54–1.34) 0.48
Diabetes mellitus 1.60 (0.96–2.66) 0.073
Psychological factorsa
High negativity/low inhibitionb 1.10 (0.59–2.08) 0.76
High negativity/high inhibitionc 1.92 (1.22–3.01) 0.005
aPatients with a score 9 on the negative affectivity scale were used as
comparator group.
bScore 10 on the negative affectivity scale and 9 on the social
inhibition scale coded as 1.
cScore 10 on the negative affectivity scale and 10 on the social
inhibition scale coded as 1.
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more evidence for the notion that social inhibition is a
psychological factor that is distinctly different from nega-
tive affect. The findings also underscore the importance of
not only focusing on one psychological risk factor at a time
but also to take into account the potential interaction
effect of psychological factors on cardiac prognosis.31
There are several pathways through which social inhi-
bition may modulate the effect of negative emotions on
clinical outcome. Pathophysiological factors comprise one
pathway.32 Inhibited individuals suppress the outward signs
of inner feelings.33 This inhibition of self-expression, in
turn, is related to enhanced cardiovascular reactivity to
stress,11 decreased cardiovascular recovery from stress,34
and reduced heart rate variability.14 In the latter study,
social inhibition and reduced heart rate variability were
independent predictors of post-MI mortality with the
largest risk incurred to patients with both risk factors.
Finally, inhibited individuals perceive the social world
as threatening,10 causing enhanced cellular immune
responses12,13 and increased levels of pro-inflammatory
cytokines under stress.15
Behavioural factors provide another potential pathway.32
An emotionally inhibited coping style may impede com-
munication between patient and physician and result in the
physician overlooking psychosocial issues (e.g. depression),
which could be potentially damaging to the health of
cardiac patients.16 Inhibited individuals appear quiet on
the surface, but they may actually feel tense and insecure
when with others and tend to experience substantial
personal distress.9,35 In addition, inhibition may be associ-
ated with non-compliance. In women with the human
immunodeficiency virus at risk of cancer, an inhibited inter-
personal style was associated with non-adherence to sched-
uled outpatient visits.17 The socially inhibited may also be
less likely to engage in health-promoting behaviours.18
Accordingly, patients from the present study who were
high in both negativity and inhibition were less likely to
quit smoking.
Preliminary evidence shows that it is possible to circum-
vent the deleterious effects of negative emotions and
social inhibition on cardiac prognosis, as a reduction in
these emotions through cardiac rehabilitation36 and the
use of anti-depressants37 have been shown to lead to
improved prognosis. With inhibited patients, it will be
particularly important for cardiologists and nurses to
be alert as to the communication between themselves and
the patient and to be persistent in asking about symptom
levels, adherence to treatment and health-promoting beha-
viours, such as smoking cessation. A well-established rapport
with the health-care staff may in time enable the patient
to feel more comfortable and free in expressing him- or
herself, in turn, enhancing compliance and reducing the
risk of adverse clinical outcome.
These findings should be interpreted with some caution.
Psychological factors were not assessed at the time of the
index event so as to present patients in a stable cardiac
condition. Although this may have biased the results, as
patients who died between 0 and 6 months following PCI
did not have a psychological assessment, a similar approach
has been adopted in other studies of PCI patients for the
very same reason.38,39 In addition, there were significant
differences on some baseline characteristics between
responders and non-responders. Hence, we do not know
whether the present results are generalizable to the total
sample. We also had no information on the potential clinical
confounders history of heart failure, left ventricular dys-
function, chronic obstructive pulmonary disease, cerebro-
vascular disease, and peripheral vascular disease or on the
use of pharmacotherapy and previous history of depression.
However, previous history of depression has not been shown
to increase the risk of cardiac events.40 Finally, we did not
have information on life-events as potential triggers of
cardiac endpoints.41
Despite these limitations, an advantage of this study is
that it reflects the ‘real world’ of interventional cardiology,
as no exclusion criteria were applied. Of note, 68% of the
patients included in the RESEARCH registry would not have
qualified for inclusion in clinical trials because of their
more complex clinical profile.42 Moreover, the present find-
ings are consistent with those of previous research20 and
also expanding our knowledge of the interaction between
psychological factors in relation to prognosis. Future
studies are warranted to determine the nature of social inhi-
bition and its most toxic components in terms of cardiovas-
cular disease progression. As suggested by Habra et al.,13
is it ‘emotional inhibition’ or ‘behavioural inhibition’ that
renders patients at risk? Given that both aspects have
been shown to have physiological correlates,43–45 they
both seem to be likely candidates to explore the pathways
through which inhibition modulates the effect of negative
emotions on prognosis.
In conclusion, the findings of the present study highlight
the role of social inhibition as an emerging psychological
factor, which may modulate the effect of negative emotions
on cardiac prognosis. These findings indicated that it was
the interaction effect of social inhibition and negative
emotions, rather than negative emotions per se, which
had a deleterious effect on clinical outcome following PCI.
Therefore, the role of social inhibition as a modulating
factor should not be overlooked in clinical research and
practice also not in the drug-eluting stent era, given that
drug-eluting stents have not been shown to confer any
benefits on survival.1–3
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